id:"swepub:oai:gup.ub.gu.se/56077"
Search: id:"swepub:oai:gup.ub.gu.se/56077" > Impact of age on le...
- 1 of 1
- Previous record
- Next record
- To hitlist
- Gerdts, E. (author)
Impact of age on left ventricular hypertrophy regression during antihypertensive treatment with losartan or atenolol (the LIFE study)
- Article/chapterEnglish2004
Publisher, publication year, extent ...
- 2004
Numbers
- LIBRIS-ID:oai:gup.ub.gu.se/56077
- https://gup.ub.gu.se/publication/56077URI
Supplementary language notes
- Language:English
Part of subdatabase
- SwePubSwePub
Classification
Notes
- To assess the influence of age on changes in left ventricular (LV) mass and geometry during antihypertensive treatment, we related age to clinical and echocardiographic findings before and after 4 years of antihypertensive treatment in a subset of 560 hypertensive patients without known concurrent disease in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, which randomized patients to blinded losartan- or atenolol-based treatment. Patients >/=65 years (older group) included more women and patients with isolated systolic hypertension or albuminuria (all P<0.05). Compared to patients <65 years, older patients had higher pulse pressure, LV mass, and prevalence of concentric hypertrophy at baseline (78 vs 69 mmHg, 234 vs 224 g, and 28 vs 16%, respectively, all P<0.01), while the mean blood pressure did not differ. Over 4 years, reductions in LV mass and the mean blood pressure were similar in both groups, but older patients more often had residual hypertrophy (31 vs 15%, P<0.001) with a preponderance of eccentric geometry. In multivariate analysis of 4-year change in LV mass controlling for baseline mass, larger hypertrophy reduction was associated with losartan treatment, while age, gender, body mass index, and 4-year change in pulse pressure and albuminuria did not enter (Multiple R (2)=0.40, P<0.001). Thus, in up-to-80-year-old hypertensive patients with left ventricular hypertrophy, age did not significantly attenuate hypertrophy reduction during antihypertensive treatment, although residual hypertrophy was more prevalent in older patients as a consequence of higher initial LV mass.
Subject headings and genre
- Age Factors
- Aged
- Aged
- 80 and over
- Antihypertensive Agents/*therapeutic use
- Atenolol/*therapeutic use
- Female
- Follow-Up Studies
- Heart Ventricles/ultrasonography
- Humans
- Hypertension/drug therapy
- Hypertrophy
- Left Ventricular/drug therapy/*ultrasonography
- Losartan/*therapeutic use
- Male
- Middle Aged
- Remission Induction
- Time Factors
Added entries (persons, corporate bodies, meetings, titles ...)
- Roman, M. J. (author)
- Palmieri, V. (author)
- Wachtell, K. (author)
- Smith, G. (author)
- Nieminen, M. S. (author)
- Dahlöf, Björn,1953Gothenburg University,Göteborgs universitet,Hjärt-kärlinstitutionen,Cardiovascular Institute(Swepub:gu)xdahbj (author)
- Devereux, R. B. (author)
- Göteborgs universitetHjärt-kärlinstitutionen (creator_code:org_t)
Related titles
- In:J Hum Hypertens18:6, s. 417-220950-9240
Internet link
Find in a library
- J Hum Hypertens (Search for host publication in LIBRIS)
To the university's database
- 1 of 1
- Previous record
- Next record
- To hitlist
Find more in SwePub
- By the author/editor
- Gerdts, E.
- Roman, M. J.
- Palmieri, V.
- Wachtell, K.
- Smith, G.
- Nieminen, M. S.
- show more...
- Dahlöf, Björn, 1 ...
- Devereux, R. B.
- show less...
- Articles in the publication
- J Hum Hypertens
- By the university
- University of Gothenburg
Search outside SwePub
- Extend your search to:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - National Library Systems
- LIBRIS.kb.se
